14 past transactions

Osmind

Series B in 2022
Osmind is a San Francisco–based public benefit corporation led by scientists, technologists, and psychiatrists to advance new evidence-based medicine that helps people living with moderate to severe mental health conditions. For more information, please visit osmind.org.

Blackrock Neurotech

Convertible Note in 2021
Blackrock Neurotech’s mission is to provide innovative tools and neurotech expertise to translate technology into a novel, implantable clinical solutions that improve human lives.

Ceretype Neuromedicine

Convertible Note in 2021
Ceretype has pioneered the integration of fMRI into therapeutic applications in neuropsychiatry. Our uniquely scalable platform makes targeted biomarkers accessible, delivering actionable insights for our pharma/biotech partners. Our decades of expertise across neuromedicine, brain imaging, and industry processes enables innovations that will ultimately transform patient care.

Ksana Health

Seed Round in 2021
Ksana Health focuses on collecting data related to mental health and transferring that data from users to healthcare practitioners through an app. It was founded in 2019 and is based in Eugene, Oregon.

Eikon Therapeutics

Series A in 2021
Eikon Therapeutics is a biopharmaceutical company that focuses on developing innovative technologies for drug discovery. The company utilizes advanced live-cell resolution microscopy and engineering to identify and create new therapeutic candidates. Eikon Therapeutics aims to enhance the understanding of biological processes at a cellular level, supporting targeted treatment development. The company’s approach integrates biology, engineering, and chemistry to streamline the drug discovery process. Through its proprietary platforms, Eikon Therapeutics seeks to advance clinical programs and expand its pipeline of potential medications.

OccamzRazor

Convertible Note in 2021
OccamzRazor combines machine learning and first-in-class biological techniques to improve outcomes in drug discovery and development. Our analysis pipeline consists of two proprietary technologies, Panoramic AI and RazorBrain. Together, they are designed to extract data from unstructured text sources (publications, patient reported outcomes, etc.) and join them with structured data (genomics, proteomics, phenomics, etc.) to generate stronger drug discovery hypotheses and more valuable insights. Successful applications include data extraction and curation from biomedical text, novel target identification, and drug repurposing/repositioning.

Sana Health

Seed Round in 2020
Sana Health is an audio-visual neuromodulation device, that provides anxiety relief on-demand - multiple applications in pain and mental health, 2 pivotal studies are underway in Fibromyalgia (FDA designated breakthrough device) and Neuropathic Pain. Anxiety and PTSD trials starting in Q2 2022, DoD grant for PTSD. SOSV, Founders Fund, Noetic Fund, Harmonix, Dreamit, Esplanade, Bridge Builders Collective, Menlo Ventures.

Delix Therapeutics

Convertible Note in 2020
Delix Therapeutics is a neuroscience company focused on harnessing the power of psychoplastogens—novel neuroplasticity-promoting therapeutics—to better treat mental health disorders at scale. The company was founded in 2019 and is headquartered in Boston, Massachusetts.

Enable Medicine

Venture Round in 2020
Enable Medicine is a biotechnology company that accelerates insight discovery by generating, managing, and analyzing spatial biology data on the enable cloud platform. Run experiments, decrease costs, and accelerate time to insight. The Enable Cloud Platform provides a collaborative ecosystem and tools for generating, visualizing, and analyzing many biological image formats. Enable Medicine was established in 2019 by Aaron Mayer and Sunil Bodapati in Menlo Park, California.

Perception Neuroscience

Convertible Note in 2020
Perception Neuroscience is a biopharmaceutical company focused on developing innovative therapies in neuropsychiatry.

Cambrian Biopharma

Series A in 2019
Cambrian Biopharma is building the medicines that will modernize healthcare in the 21st century – therapeutics to lengthen healthspan, the period of life spent in good health. As a Distributed Development Company (or DisCo), Cambrian is advancing multiple scientific breakthroughs, each targeting a biological driver of aging. Our approach is to develop interventions that treat specific diseases first, then deploy them as preventative medicines to improve quality of life/overall quality of life as we age.

atai Life Sciences

Secondary Market in 2019
Atai Life Sciences is a biotechnology company that develops therapies for mental health disorders. The company focuses on creating treatments using psychedelic compounds and other methods to address conditions such as depression, anxiety, and substance use disorders. Atai collaborates with various partners and research institutions to advance its drug development pipeline, which includes several clinical-stage programs. The product portfolio includes therapies that utilize research in psychedelics and neuroscience. Atai's lead programs feature ketamine-based treatments and other compounds aimed at improving mental well-being. The company works with experts in the field to ensure the efficacy and safety of its therapies. Atai Life Sciences has received recognition for its work in mental health treatment, securing partnerships and funding to support its research initiatives. The company has been acknowledged for its contributions to psychiatry and has gained attention for its efforts to advance the understanding and treatment of mental health disorders.

Psy Therapeutics

Seed Round in 2019
Psy Therapeutics is discovering and developing novel medicines to improve the lives of people affected by central nervous system (CNS) disorders. The company focuses on anxiety, depression, and dementia to improve neuropsychiatric care.

COMPASS Pathways

Convertible Note in 2019
Compass Pathways is a mental health care company that focuses on developing therapies for treatment-resistant depression. The company is involved in researching and developing psilocybin therapy, a psychedelic compound found in certain mushrooms, as a potential treatment for depression. Compass Pathways conducts clinical trials and research to assess the safety and efficacy of psilocybin-assisted therapy in patients who have not responded to conventional depression treatments. The company's goal is to bring evidence-based innovation to mental health care and address the significant unmet need for effective and accessible treatments for depression.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.